Skip to main content

Table 2 General characteristics of the participants

From: A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

  PCa and ADT (n= 26,082) p* PCa w/ADT (n= 51,605) p** Controls (n= 1,066) p***
Age (years) 72.3 ± 3.12 > 0.05 70.2 ± 2.81 > 0.05 70.3 ± 3.30 > 0.05
ADT time (months) 36.9 ± 31.2 --- --- --- --- ---
Total BMD (g/cm2) 0.90 ± 0.34 0.031 1.07 ± 0.11 0.760 0.96 ± 0.20 0.895
LS BMD (g/cm2) 1.02 ± 0.10 0.083 1.10 ± 0.13 0.806 1.05 ± 0.18 0.868
TH BMD (g/cm2) 0.89 ± 0.08 0.002 1.010.08 0.823 0.97 ± 0.03 0.211
t score (Total) -1.30 ± 1.10 0.282 -0.26 ± 1.14 --- --- ---
t score (LS) -0.27 ± 1.21 0.031 0.25 ± 0.07 --- --- ---
t score (TH) -0.94 ± 0.24 0.021 -0.55 ± 0.07 --- --- ---
z score (Total) -0.30 ± 0.69 0.164 0.54 ± 0.15 --- --- ---
z score (LS) -0.27 ± 1.31 --- --- --- --- ---
z score (TH) -0.33 ± 0,65 0.555 0.05 ± 0.35 --- --- ---
Osteoporosis (%) 5.30 < 0.001 2.89 < 0.001 10.3 < 0.001
Osteopenia (%) 1.01 < 0.001 0.15 < 0.001 1.4 0.278
Fracture (%) 17.56 < 0.001 15.62 < 0.001 1.5 < 0.001
Vertebral fracture (%) 2.96 < 0.001 1.90 --- --- ---
Superior member fracture (%) 4.45 < 0.001 2.47 --- --- ---
Inferior member fracture (%) 9.77 < 0.001 7.38 --- --- ---
  1. LS: Lumbar spine; TH: Total hip
  2. *: PCa and ADT vs PCa w/ADT
  3. **: PCa w/ADT vs Controls
  4. ***: Controls vs PCa and ADT